Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

doi:10.3390/curroncol29070352

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

Current oncology (Toronto, Ont.) - 22 Jun 2022

Kuang Shelley, Fung Andrea S, Perdrizet Kirstin A, Chen Kaitlin, Li Janice J N, Le Lisa W, Cabanero Michael, Karsaneh Ola Abu Al, Tsao Ming S, Morganstein Josh, Ranich Laura, Smith Adam C, Wei Cuihong, Cheung Carol, Shepherd Frances A, Liu Geoffrey, Bradbury Penelope, Pal Prodipto, Schwock Joerg, Sacher Adrian G, Law Jennifer H, Stockley Tracy L, Leighl Natasha B

Abstract excerpt

In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic alterations may derive additional clinical benefit from targeted treatment compared to cytotoxic chemotherapy. Current guidelines recommend extensive testing with next generation sequencing (NGS) panels. We investigated the impact of using a targeted NGS panel (TruSight Tumor 15, Illumina) as reflex testing for NSCLC samples at a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to High-Throughput Nucleotide Sequencing

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA modifications and cancer

Source

Open in PubMed Open full text

Identifiers

PMID: 35877212
DOI: 10.3390/curroncol29070352
PMCID: PMC9319994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.PMID 35877212Read ↗

Next-Generation Sequencing in Lung Cancers-A Single-Center Experience in Taiwan.Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.Semantic proximity Read ↗

Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experienceSemantic proximity Read ↗

Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.Semantic proximity Read ↗

Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.Semantic proximity Read ↗

Clinical mutational profiling of 1006 lung cancers by next generation sequencingSemantic proximity Read ↗

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.Semantic proximity Read ↗

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.Semantic proximity Read ↗

Clinical next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

Genomic Landscape of NSCLC in the Republic of IrelandSemantic proximity Read ↗

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.